|
1
|
Clemens JQ, Meenan RT, Rosetti MC, Gao SY
and Calhoun EA: Prevalence and incidence of interstitial cystitis
in a managed care population. J Urol. 173:98–102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choe JH, Son H, Song YS, Kim JC, Lee JZ
and Lee KS: Prevalence of painful bladder syndrome/interstitial
cystitis-like symptoms in women: A population-based study in Korea.
World J Urol. 29:103–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang ZY and Bjorling DE: Tumour necrosis
factor-α induces expression and release of interleukin-6 by human
urothelial cells. Inflammation Res. 60:525–532. 2011.
|
|
4
|
Imamura T, Igawa Y, Ogawa T, Homma T, Seki
S, Ishizuka O, Satoshi A, Homma Y and Nishizawa O: Expression level
of CXCL10 peptide in bladder urothelium and urine as possible
biomarkers for diagnosis of ulcerative interstitial cystitis. Eur
Urol Suppl. 9:2122010. View Article : Google Scholar
|
|
5
|
Richter B, Roslind A, Hesse U, Nordling J,
Johansen JS, Horn T and Hansen AB: YKL-40 and mast cells are
associated with detrusor fibrosis in patients diagnosed with
bladder pain syndrome/interstitial cystitis according to the 2008
criteria of the European Society for the Study of Interstitial
Cystitis. Histopathology. 57:371–383. 2010. View Article : Google Scholar
|
|
6
|
Ogawa T, Homma T, Igawa Y, Seki S,
Ishizuka O, Imamura T, Akahane S, Homma Y and Nishizawa O: CXCR3
binding chemokine and TNFSF14 over expression in bladder urothelium
of patients with ulcerative interstitial cystitis. J Urol.
183:1206–1212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lv J, Luo Y, Leng J, Xue W, Liu D and
Huang Y: Aberrant expression of monocyte chemoattractant protein-1
(mcp-1) in interstitial cystitis patients. Sci Res Essays.
5:663–667. 2010.
|
|
8
|
Kutlu O, Akkaya E, Koksal IT, Bassorgun
IC, Ciftcioglu MA, Sanlioglu S and Kukul E: Importance of
TNF-related apoptosis-inducing ligand in pathogenesis of
interstitial cystitis. Int Urol Nephrol. 42:393–399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen MC, Keshavan P, Gregory GD and Klumpp
DJ: RANTES mediates TNF-dependent lamina propria mast cell
accumulation and barrier dysfunction in neurogenic cystitis. Am J
Physiol Renal Physiol. 292:F1372–F1379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang N, Sanders AJ, Ye L, Kynaston HG and
Jiang WG: Expression of vascular endothelial growth inhibitor
(VEGI) in human urothelial cancer of the bladder and its effects on
the adhesion and migration of bladder cancer cells in vitro.
Anticancer Res. 30:87–95. 2010.PubMed/NCBI
|
|
11
|
Song YJ, Meylan F, Botson J,
Goldbach-Mansky R, Lee D and Siegel R: TL1A-DR3 interactions are
important in both adaptive and innate immunity in inflammatory
arthritis. Clin Immunol. 135:S882010. View Article : Google Scholar
|
|
12
|
Tan KB, Harrop J, Reddy M, Young P,
Terrett J, Emery J, Moore G and Truneh A: Characterization of a
novel TNF-like ligand and recently described TNF ligand and TNF
receptor superfamily genes and their constitutive and inducible
expression in hematopoietic and non-hematopoietic cells. Gene.
204:35–46. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gillenwater JY and Wein AJ: Summary of the
National Institute of Arthritis, Diabetes, Digestive and Kidney
Diseases Workshop on Interstitial Cystitis, National Institutes of
Health, Bethesda, Maryland, August 28–29, 1987. J Urol.
140:203–206. 1988.PubMed/NCBI
|
|
14
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taraban VY, Slebioda TJ, Willoughby JE,
Buchan SL, James S, Sheth B, Smyth NR, Thomas GJ, Wang EC and
Al-Shamkhani A: Sustained TL1A expression modulates effector and
regulatory T-cell responses and drives intestinal goblet cell
hyperplasia. Mucosal Immunol. 4:186–196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pobezinskaya YL, Choksi S, Morgan MJ, Cao
X and Liu ZG: The adaptor protein TRADD is essential for TNF-like
ligand 1A/death receptor 3 signaling. J Immunol. 186:5212–5216.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang YJ, Kim WJ, Bae HU, Kim DI, Park YB,
Park JE, Kwon BS and Lee WH: Involvement of TL1A and DR3 in
induction of pro-inflammatory cytokines and matrix
metalloproteinase-9 in atherogenesis. Cytokine. 29:229–235. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Young HA and Tovey MG: TL1A: a mediator of
gut inflammation. Proc Natl Acad Sci USA. 103:8303–8304. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Altamirano CV, Pang S, Li LY and Berenson
JR: Vascular endothelial growth inhibitor (vegi) inhibits the
growth of multiple myeloma plasma cells and induces their
apoptosis. Blood. 98:638A2001.
|
|
20
|
Abdel-Mageed AB and Ghoniem GM: Potential
role of rel/nuclear factor-kappaB in the pathogenesis of
interstitial cystitis. J Urol. 160:2000–2003. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamada T, Nishimura M and Mita H:
Increased number of apoptotic endothelial cells in bladder of
interstitial cystitis patients. World J Urol. 25:407–413. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsieh JH, Chen CY and Kuo HC: Increased
apoptosis and decreased junction protein expression of urothelium
due to suburothelial inflammation in patients with interstitial
cystitis/painful bladder syndrome. Neurourol Urodynamics.
29:1138–1140. 2010.
|
|
23
|
Shie JH, Liu HT and Kuo HC: Increased cell
apoptosis of urothelium mediated by inflammation in interstitial
cystitis/painful bladder syndrome. Urology. 79:484 e7–e13.
2012.
|
|
24
|
Wang W, Zhang N, Zhu XH, He ZS, Wahafu W,
Xu ZQ and Yang Y: Involvement of TL1A and DR3 in induction of
ischaemia and inflammation in urinary bladder dysfunction in the
elderly. Mol Med Rep. 6:434–438. 2012.PubMed/NCBI
|
|
25
|
Wang L, Pan W, Zhu FL, Jiao BH, Lou YH,
Xiao Y and Qi ZT: Cloning, expression and biological activity of
VEGI(151), a novel vascular endothelial cell growth inhibitor. Acta
Biochimica Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai).
32:485–489. 2000.PubMed/NCBI
|
|
26
|
Chen X, Wu JH, Liu HN, He Z, Gu M, Wang N,
Ma J, Hu J, Xia L, He H, Yuan J, Li J, Li L, Li M and Zhu X:
Approaches to efficient production of recombinant angiogenesis
inhibitor rhVEGI-192 and characterization of its structure and
antiangiogenic function. Protein Sci. 19:449–457. 2010.PubMed/NCBI
|
|
27
|
Pontari MA, Hanno PM and Ruggieri MR:
Comparison of bladder blood flow in patients with and without
interstitial cystitis. J Urol. 162:330–334. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altuntas CZ, Daneshgari F, Sakalar C,
Goksoy E, Gulen MF, Kavran M, Qin J, Li X and Tuohy VK:
Autoimmunity to uroplakin II causes cystitis in mice: a novel model
of interstitial cystitis. Eur Urol. 61:193–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanno PM, Burks DA, Clemens JQ, Dmochowski
RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer
RD, Newman D, Nyberg L Jr, Payne CK, Wesselmann U and Faraday MM;
Interstitial Cystitis Guidelines Panel of the American Urological
Association Education and Research Inc: AUA guideline for the
diagnosis and treatment of interstitial cystitis/bladder pain
syndrome. J Urol. 185:2162–2170. 2011. View Article : Google Scholar
|
